TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04896879

Intervention type: BEHAVIORAL
Intervention: interviews
Description: semi-structured interviews will be conducted in patients with major LARS and their informal caregiver to explore their experiences and needs. Focus groups will be perfomed with healthcare professionals of several professions.

Intervention type: BEHAVIORAL
Intervention: interviews
Description: semi-structured interviews will be conducted in patients with major LARS and their informal caregiver to explore their experiences and needs. Focus groups will be perfomed with healthcare professionals of several professions.

Intervention type: BEHAVIORAL
Intervention: interviews
Description: semi-structured interviews will be conducted in patients with major LARS and their informal caregiver to explore their experiences and needs. Focus groups will be perfomed with healthcare professionals of several professions.
Study: NCT04315220

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Intervention
Description: No Intervention
Study: NCT01750957

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: orally daily, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917523
Description: Dose A orally daily, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917523
Description: Dose B orally daily, 12 weeks
Study: NCT02718469

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ebola Vaccine - low dose
Description: 2 x 0.5ml vaccine will be given as intramuscular injections on each of day 1 and day 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ebola Vaccine - mid dose
Description: 2 x 0.5ml vaccine will be given as intramuscular injections on each of day 1 and day 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ebola Vaccine - high dose
Description: 2 x 1.0ml vaccine will be given as intramuscular injections on each of day 1 and day 28
Study: NCT02959710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-1202 mixed in Ensure®
Description: 60 g AC-1202 (shaken in approximately 8 oz \[237 mL of Ensure® Original\] at Hour 0 on Day 1)
Study: NCT02718469

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 x 0.5ml or 2 x 1.0ml placebo will be given as intramuscular injections on each of day 1 and day 28 depending on cohort
Study: NCT03142789

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Initial bolus (Certa and standard catheter groups)
Description: 10 ml of ropivacaine 0,75% will be used to ensure correct position of the needle and to expand the adductor canal, followed by injection of another 10 ml of ropivacaine 0.75% via the catheter during real time US imaging to ensure correct placement of the catheter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Initial bolus (Certa and standard catheter groups)
Description: 10 ml of ropivacaine 0,75% will be used to ensure correct position of the needle and to expand the adductor canal, followed by injection of another 10 ml of ropivacaine 0.75% via the catheter during real time US imaging to ensure correct placement of the catheter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Initial bolus (Single bolus group)
Description: 20 ml of ropivacaine 0.75%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent boluses (Certa and standard catheter groups)
Description: 20 ml of ropivacaine 0.2% every 8 hour in the catheter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent boluses (Certa and standard catheter groups)
Description: 20 ml of ropivacaine 0.2% every 8 hour in the catheter

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent boluses (Single bolus group)
Description: 0.1ml of ropivacaine 0.2% every 8 hour in the sham catheter
Study: NCT04863105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate tablets(Zecke ®250 mg);Abiraterone acetate tablets(250 mg)
Description: Subjects were allocated to one of three groups randomly and equally with a 7-day washout interval between the two periods.Abiraterone acetate tablets(Zecke ® 250 mg,Batch number:VYCB manufactured by Patheon Inc.)and Abiraterone acetate tablets(250 mg,Batch number:17F0023DD9 manufactured by Qilu Pharmaceutical Co., Ltd) were used in this study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate tablets(Zecke ®250 mg);Abiraterone acetate tablets(250 mg)
Description: Subjects were allocated to one of three groups randomly and equally with a 7-day washout interval between the two periods.Abiraterone acetate tablets(Zecke ® 250 mg,Batch number:VYCB manufactured by Patheon Inc.)and Abiraterone acetate tablets(250 mg,Batch number:17F0023DD9 manufactured by Qilu Pharmaceutical Co., Ltd) were used in this study.
Study: NCT01989442

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: binasal prongs
Description: patients randomized to binasal prongs for NIV will use binasal prongs as an interface during continuous positive airway pressure support

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nasal mask
Description: patients randomized to nasal mask for NIV will use nasal mask as an interface during continuous positive airway pressure support
Study: NCT00854139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, anti-thymocyte globulin
Description: Cyclophosphamide 60 mg/kg IV on Day -5, -4 Anti-thymocyte globulin 20 mg/kg IV on Day -1, Day +1, +3, +5~Cyclosporine starting on Day -1 at 5 mg/kg daily I.V. and reduced to 3 mg/kg on Day +4, and adjusted to provide a trough whole blood concentration of 250-400 ng/mL. The route of administration will be changed to oral as soon as the patient is able to tolerate oral medications

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney transplant
Description: On Day 0 the renal transplant is performed according to standard surgical techniques, preferably using an iliac fossa, extraperitoneal approach

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thymic irradiation
Description: Thymic irradiation 7 Gy on Day -1

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone marrow transplant from a related donor
Description: • Donor bone marrow (\> 2 x 108 nucleated cells/kg of recipient body weight) is prepared for infusion according to the standard procedure at the medical center. A total of 15,000 Units of heparin is mixed with the marrow, which is infused at a rate of 300-500 cc/hr. The infusion begins in the operating room as soon as the vascular anastomosis of the renal allograft has been completed. Protamine, 25 mg, is administered I.V. after completion of the first half of the bone marrow infusion. If a partial thromboplastin time measured after completion of the marrow infusion is \> 60 seconds, the protamine treatment shall be repeated
Study: NCT00772200

Intervention type: PROCEDURE
Intervention: Cognitive Assessment
Description: Complete COG Standard Neuropsychological and Behavioral Battery

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01412216

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil (Omega-3 Fatty Acids)
Description: fish oil-4.4gm/day x 5 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fish Oil (Omega-3 Fatty Acids)
Study: NCT03403738

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bounce Back Now
Description: web/smartphone-based intervention for disaster victims
Study: NCT03527030

Intervention type: OTHER
Intervention: Survey on Use of Tobacco Products in the General Population
Description: Face-to-face survey to estimate the prevalence of current tobacco use status in the general population of the Greater London area.
Study: NCT03403738

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: enhanced usual care
Description: enhanced usual care with list of resources
Study: NCT03527030

Intervention type: OTHER
Intervention: Survey on Use of Tobacco Products in IQOS Users
Description: Online survey to describe patterns of use in users of IQOS residing in the Greater London area.
Study: NCT03561961

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Hypo-fractionation
Description: 66-68Gy in 25#

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Extreme Hypo-fractionation
Description: 35-36.25 Gy in 5#
Study: NCT02511990

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3 mg/kg, single dose IV administration of 10-1074
Description: 3 mg/kg, single dose IV administration of 10-1074

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3 mg/kg, single dose IV administration of 10-1074
Description: 3 mg/kg, single dose IV administration of 10-1074
Study: NCT03148938

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Digital Assessment on mobile
Description: The digital assessment is composed on 4 tests:~* walking test~* coordination test~* attention test~* vision test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Assessment on mobile
Description: The digital assessment is composed on 4 tests:~* walking test~* coordination test~* attention test~* vision test
Study: NCT02511990

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10 mg/kg, single dose IV administration of 10-1074
Description: 10 mg/kg, single dose IV administration of 10-1074

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10 mg/kg, single dose IV administration of 10-1074
Description: 10 mg/kg, single dose IV administration of 10-1074

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 mg/kg, single dose IV administration of 10-1074
Description: 30 mg/kg, single dose IV administration of 10-1074

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 mg/kg, single dose IV administration of 10-1074
Description: 30 mg/kg, single dose IV administration of 10-1074

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 mg/kg, single dose IV administration of 10-1074
Description: 30 mg/kg, single dose IV administration of 10-1074

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 mg/kg, single dose IV administration of 10-1074
Description: 30 mg/kg, single dose IV administration of 10-1074
Study: NCT04473846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PK general anesthesia
Description: Patients will be anesthetized using Fentanyl (2 mcg/kg) and Propofol (1-2 mg/kg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PFK combination
Description: Each patient received an initial dose of 0.05 ml/kg from the solution, then after waiting for 60 seconds, another 0.05 ml/kg were given. Maintenance was given as boluses of 0.025 ml/kg every three to five minutes.
Study: NCT02297048

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Potassium depletion
Description: Healthy subjects will be submitted twice at 15-30 day interval, to a low potassium diet (20mmol/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potassium depletion
Description: Healthy subjects will be submitted twice at 15-30 day interval, to a low potassium diet (20mmol/day)
Study: NCT02682771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bilevel positive airway pressure
Description: The use of positive airway pressure airway seeking in the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PowerBreathe
Description: Exercises with inspiratory load has the aim to trainning inspiratory muscle in strength and endurance, thus, could help to prevent postoperative complications.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Respiratory Physiotherapy (CRP)
Description: CRP consisted of diaphragmatic respiratory exercises, deep inhalation exercises, inhalations fragmented two to three times and respiratory exercises associated with shoulder flexion movements and extension of the upper limbs. One series of 10 repetitions was carried out for each exercise. Walking sessions and preventive exercises for deep vein thrombosis were carried out

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Respiratory Physiotherapy (CRP)
Description: CRP consisted of diaphragmatic respiratory exercises, deep inhalation exercises, inhalations fragmented two to three times and respiratory exercises associated with shoulder flexion movements and extension of the upper limbs. One series of 10 repetitions was carried out for each exercise. Walking sessions and preventive exercises for deep vein thrombosis were carried out

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional Respiratory Physiotherapy (CRP)
Description: CRP consisted of diaphragmatic respiratory exercises, deep inhalation exercises, inhalations fragmented two to three times and respiratory exercises associated with shoulder flexion movements and extension of the upper limbs. One series of 10 repetitions was carried out for each exercise. Walking sessions and preventive exercises for deep vein thrombosis were carried out
Study: NCT01356927

Intervention type: DRUG
Intervention: DMPA
Description: DMPA 150 mg IM given on the day of mifepristone 200 mg po for medical abortion

Intervention type: DRUG
Intervention: Etonogestrel implant
Description: Etonogestrel implant placed at the time of mifepristone 200 mg po for medical abortion
Study: NCT01033851

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Based Stress Reduction
Description: 8 week course

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress Management Education
Description: 8 week course
Study: NCT02795026

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: Myofascial trigger point release technique is a technique used to help ease tight muscles. This technique involves palpating the tight muscle for the 'knot'/trigger point and gently applying pressure for 30-60 seconds to help ease out the trigger point.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: Myofascial trigger point release technique is a technique used to help ease tight muscles. This technique involves palpating the tight muscle for the 'knot'/trigger point and gently applying pressure for 30-60 seconds to help ease out the trigger point.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trigger point dry needling
Description: Trigger point dry needling is a treatment technique involving the use of a single, disposable, fine filament acupuncture needle. Here the tight muscle is palpated and the acupuncture needle is directed towards the trigger point. The insertion of the needle is not felt, however the twitch reflex elicited to ease off the trigger point can be felt . This can be sore, but lasts only for a few seconds. Trans-perineal trigger point dry needling is an effective dry needling technique for the pelvic floor muscles done externally, targeting the trigger points in the pelvic floor muscles.
Study: NCT02991313

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endocardial Ablation Procedure
Study: NCT04080999

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: r-TMS
Description: The interventions have a total administration time of 75 minutes per day.For TMS stimulation, the coil will be positioned tangentially on the target area. Each r-TMS session will last 15 minutes and will be administered every other day (e.g. Monday-Wednesday-Friday, Monday-Wednesday-Friday, Monday). The visual scanning treatment involves the presence of a therapist, who administers various visual scanning tasks, used to increase patient's awareness and to teach strategies to improve spatial exploration abilities (Pizzamiglio et al.,1992).Trainings include three increasing levels of difficulty (9 possible combinations). Each level of difficulty will be exercised until the patient reaches a level of accuracy of 75%. The CCT will be carried out in 50 minutes sessions for 5 days a week within 15 days (11 sessions in total). On the days when the r-TMS is also administered, the administration of the CCT will immediately follow the brain stimulation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM
Description: Device: SHAM Stimulation and Visual Scanning training. In the control group, the coil of the r-TMS will be positioned at 90° on the target area, thus no specific cortical modulation will be implemented (SHAM stimulation). For the SHAM group, the CCT protocol will be administered with the same modalities and time frame as detailed for the intervention group.
Study: NCT03922139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA Injection
Description: Ultrasound guided 1 mg/1 mL injection.~25 units of Botox will be injected 2 cm proximal and 2 cm distal to the midpoint of the tibialis anterior muscle.
Study: NCT03343639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg Serlopitant Tablets
Description: Serlopitant Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo Tablets
Description: Placebo Tablets
Study: NCT03561987

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: There are two components to the procedure. First, a small stomach pouch, approximately one ounce or 30 milliliters in volume, is created by dividing the top of the stomach from the rest of the stomach. Next, the first portion of the small intestine is divided, and the bottom end of the divided small intestine is brought up and connected to the newly created small stomach pouch. The procedure is completed by connecting the top portion of the divided small intestine to the small intestine further down so that the stomach acids and digestive enzymes from the bypassed stomach and first portion of small intestine will eventually mix with the food.

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: There are two components to the procedure. First, a small stomach pouch, approximately one ounce or 30 milliliters in volume, is created by dividing the top of the stomach from the rest of the stomach. Next, the first portion of the small intestine is divided, and the bottom end of the divided small intestine is brought up and connected to the newly created small stomach pouch. The procedure is completed by connecting the top portion of the divided small intestine to the small intestine further down so that the stomach acids and digestive enzymes from the bypassed stomach and first portion of small intestine will eventually mix with the food.
Study: NCT03240120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Description: Pradaxa 150 mg hard capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinzaparin
Description: Tinzaparin 175 iu/kg daily will be started after the diagnosis of VTE is confirmed
Study: NCT03912064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is an antibody that acts against CTLA-4

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD25hi Treg depleted DLI
Description: Donor lymphocyte product
Study: NCT01498601

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced oral care protocol
Description: * Changing mouth suction equipment every 24 hours~* Mouth assessment every 2-4 hours~* Cleansing mouth with toothbrush every 12 hours~* Cleansing oral mucosa with oral rinse solution every 2-4 hours~* Moisturize mouth/lips with swab and standard mouth moisturizer every 4 hours~* Suction mouth and throat as needed~* Head of the bed elevated to a minimum of 30° during oral care
Study: NCT00003700

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Courses I, II, IV, V: 5 ug/kg/d subQ injection Day 4 until ANC \> 5,000 uL after nadir: 7 day minimum for Courses I \& IV
Study: NCT02915809

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC3110B vaccine
Description: 0.5mL, Intramuscular
Study: NCT05108714

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intravenous cannulation after intradermal injection of lidocaine via MicronJet600 microneedle device (1)
Description: Intradermal administration of 100 µL of lidocaine (registrational number LS001516 by Federal Service for Surveillance in Healthcare of Russian Federation) via MicronJet600 microneedle device at the site of antecubital fossa of the left arm, followed by the insertion of 18G catheter in a cubital vein immediately after the lidocaine administration.
Study: NCT02915809

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GCFLU Quadrivalent Inj. vaccine
Description: 0.5mL, Intramuscular
Study: NCT00003700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase
Description: 6000 U/sq m subQ or IM injection 2X/wk for 6 doses starting on Day 5: Courses I \& IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 1200 mg/sq m IV infusion over 15-30 min Day 1 Courses I \& IV (pts \< 60y/o) 1000 mg/sq m IV infusion over 15-30 min Day 1 Courses II \& V

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 2000 mg/sq m IV infusion over 3 hrs Days 1,2, \& 3: Courses II \& V

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Description: 80mg/sq m (pts\<60y/o)OR 60mg/sq m (pts =/\>60y/o) IV infusion over 5-10 min Days 1,2,\& 3: Courses I \& IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Courses III \& VI:~25mg/sq m IV infusion Days 2, 9, and 16 5mg/sq m PO q 6 hr for 8 doses or until serum MTX \<0.05 uM after ea IV dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine
Description: 60mg/sq m/d PO every day Course VII

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: 15mg intrathecal Day 1 Courses II \& V 1000mg/sq m IV infusion over 3 hrs Days 1, 8, \& 15 and 25mg/sq m PO q 6hr x 4 doses after ea IV dose: Courses III \& VI.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 60mg/sq m/day PO Days 1-21 (pts\<60y/o) OR Days 1-7 (pts \>/= 60y/o) Courses I \& IV and Days 1-5 of ea 4 cycle in Course VII

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: 2 mg total IV infusion Days 1,8,15,\& 22 Courses I \& IV and Days 1, 8, \& 15 Courses III \& VI, and Day 1 of ea 4 wk cycle in Course VII